ClinicalTrials.gov
ClinicalTrials.gov Menu

Effectiveness of Additional Acupuncture Therapy for Lung Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01408212
Recruitment Status : Terminated (low recruiting)
First Posted : August 3, 2011
Last Update Posted : September 2, 2015
Sponsor:
Collaborator:
Pusan National University Yangsan Hospital
Information provided by (Responsible Party):
Jun-Yong Choi, Korean Medicine Hospital of Pusan National University

Brief Summary:
This study aims for evaluating the effectiveness, safety and feasibility of additional acupuncture therapy for lung cancer patients who are under chemotherapy in an inpatient setting. The acupuncture therapy will be administered during a resting period between cycles of chemotherapy.

Condition or disease Intervention/treatment Phase
Lung Cancer Procedure: Acupuncture treatment Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Study Start Date : July 2011
Actual Primary Completion Date : June 2012
Actual Study Completion Date : December 2012

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Acupuncture therapy Procedure: Acupuncture treatment

Acupuncture treatment will be performed by licensed doctors in Korean Medicine using 0.20 mm (diameter) X 0.30 mm (length) sized disposable acupuncture on seven to ten consecutive days after admission to the Korean Medicine Hospital of Pusan National University. At least two sessions and a maximum of five sessions of acupuncture therapy will be administered per day. Acupuncture points consist of common points and additional points selected for typical complaints common in patients under chemotherapy. These points are as follows.

  • Common points: LI4 (bilateral), LU5 (bilateral), LU7 (bilateral), BL13 (bilateral), BL23 (bilateral), SP3 (bilateral), LU9 (bilateral), ST36 (bilateral) and CV22
  • Additional points Nausea/vomiting PC6 (bilateral) Dyspepsia: CV12, LU6 (bilateral) Insomnia: Yintang, KI5 (bilateral) Pain: Ashi points (tender spots)




Primary Outcome Measures :
  1. Change score of Functional Assessment of Cancer Therapy-Lung (FACT-L) scale from baseline [ Time Frame: 7-10 days during a rest period between chemotherapy cycles ]

Secondary Outcome Measures :
  1. Change score of Functional Assessment of Cancer Therapy-Lung (FACT-L) scale from baseline [ Time Frame: 4-5 weeks from baseline (3-4 weeks after treatment termination) ]
  2. Change score of Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT fatigue) Scale from baseline [ Time Frame: Baseline, 7-10 days after baseline, 4-5 weeks after baseline ]
  3. Change of general condition assessment using visual analogue scale from baseline [ Time Frame: Baseline, 7-10 days after baseline, 4-5 weeks after baseline ]
  4. Adverse events [ Time Frame: From study enrollment to the last follow-up (a maximum of day 36) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • At least 18 years of age
  • Karnofsky Performance Status (KPS) 60% or more
  • Undergoing antineoplastic chemotherapy for lung cancer
  • Able to provide informed consent

Exclusion Criteria:

  • Brain metastasis, stroke or major psychiatric diseases
  • Active infection
  • Severe heart disease
  • Serious systemic diseases such as uncontrolled hypertension and diabetes mellitus
  • Acupuncture therapy within the previous three months
  • Communication disorder
  • Unwillingness to participate in the trial
  • Severe immunocompromised state (absolute neutrophils count < 1000/cubic mm)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01408212


Locations
Korea, Republic of
Pusan National University Yangsan Hospital and Korean Medicine Hospital of Pusan National University
Yangsan, Gyeongsangnam-do, Korea, Republic of, 626-770
Sponsors and Collaborators
Korean Medicine Hospital of Pusan National University
Pusan National University Yangsan Hospital
Investigators
Principal Investigator: Yun Seong Kim, PhD Pusan National University Yangsan Hospital
Principal Investigator: Jun-Yong Choi, MS Korean Medicine Hospital of Pusan National University

Responsible Party: Jun-Yong Choi, Associate professor, Korean Medicine Hospital of Pusan National University
ClinicalTrials.gov Identifier: NCT01408212     History of Changes
Other Study ID Numbers: KCRC-IRB-2011009 & L-2011-170
First Posted: August 3, 2011    Key Record Dates
Last Update Posted: September 2, 2015
Last Verified: September 2015

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases